Advances in lung cancer- Updates from ASCO 2021
Expiry Date
: 01/06/2028
CPD Units
: 3.00 Points
Rating
: Not yet rated.
This video presents an overview of the recent updates in early and advanced treatment for lung cancer from the ASCO 2021 meeting.
Keywords: lung cancer, neoadjuvant immunotherapy, adjuvant therapy, EGFR Exon 20 insertions, clinical trials
Reading material:
Educational Objectives
Educational Aim:
The aim of this article is to provide updates on early and advanced treatment for lung cancer from ASCO 2021, with a focus on neoadjuvant immunotherapy with chemotherapy and post-surgical adjuvant treatment.
Educational Outcomes:
Upon completion of this module practitioners should have a clear understanding of:
- Understand the recent updates in early and advanced treatment for lung cancer presented at ASCO
- Learn about the benefits of neoadjuvant immunotherapy with chemotherapy for lung cancer patients
- Understand the importance of individualizing treatment based on patient factors such as mutation type and toxicity
- Learn about the challenges of treating patients with CNS-only progression
- Understand the potential efficacy of new drugs such as sunbazertanip and repotrectinib for lung cancer patients with specific mutations
- Describe the implications of recent research findings on lung cancer treatment and their potential impact on patient care.
Instructions for this Module
- Read the supplied reading material and complete the quiz that follows;
- You have three attempts to pass the quiz;
- The pass grade is 70%;
- You need to pass the quiz to claim your CPD certificate;
- Please click on the CPD certificate link below to claim your CPD certificate and to update your CPD Manager.
If you need any assistance to complete this module, please Contact us